Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Sepsis Diagnostics Industry Expected To Reach By 2029, Starting From 2025 Levels?
The sepsis diagnostics market has shown significant growth in recent years. It is anticipated to expand from $0.99 billion in 2024 to $1.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.8%. The historical expansion of this market can be attributed to factors such as the increasing incidence of sepsis, heightened awareness surrounding early diagnosis, rising healthcare expenditure, the growing prevalence of hospital-acquired infections, and the increasing adoption of point-of-care testing.
The sepsis diagnostics market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $1.46 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the forecast period include an elevated demand for swift diagnostic solutions, greater capital expenditure in healthcare facilities, an intensified emphasis on individualized medical treatments, a growing occurrence of antimicrobial resistance, and an expanding application of next-generation sequencing technologies. Key trends anticipated within the same period encompass the incorporation of artificial intelligence into diagnostics, innovations in biomarker technology, progress in molecular diagnostics, a transition toward automated and digital diagnostic systems, and further developments in artificial intelligence for diagnostic purposes.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23514&type=smp
What Are The Top Growth Drivers Impacting The Sepsis Diagnostics Market Outlook?
The growing occurrence of hospital-acquired infections is anticipated to drive the expansion of the sepsis diagnostics market in the future. These infections, known as HAIs, develop during or after a patient’s stay in a healthcare facility, typically appearing 48 hours or more post-admission, and were not present upon entry. This rise in hospital-acquired infections stems from an increase in antibiotic resistance. The overuse and misuse of antibiotics in healthcare settings have led to the evolution of resistant bacteria, making infections significantly harder to treat. Sepsis diagnostics aids in the early identification of hospital-acquired infections by detecting pathogens and biomarkers, enabling timely treatment and reducing complications. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022–23, HACs were observed in 2% of public hospital admissions and 0.8% of private hospital admissions, with healthcare-associated infections being the most frequent complication. Therefore, the increasing incidence of hospital-acquired infections is a primary driver of growth in the sepsis diagnostics market.
What Are The Leading Segments Analyzed In The Sepsis Diagnostics Market?
The sepsis diagnosticsmarket covered in this report is segmented –
1) By Product: Instruments; Blood Culture Media; Assay Kits And Reagents; Software
2) By Technology: Microbiology; Molecular Diagnostics; Immunoassays; Flow Cytometry; Other Technologies
3) By Pathogen: Bacterial Sepsis; Fungal Sepsis; Viral Sepsis; Other Pathogens
4) By Method: Automated Diagnostics; Conventional Diagnostics
5) By End-Users: Hospitals And Clinics; Pathology And Reference Laboratories; Research Institutes
Subsegments:
1) By Instruments: Automated Analyzers; Point-Of-Care (PoC) Testing Devices; Microfluidic-Based Devices; Polymerase Chain Reaction (PCR) Instruments; Flow Cytometers
2) By Blood Culture Media: Aerobic Blood Culture Media; Anaerobic Blood Culture Media; Mycobacteria Blood Culture Media; Pediatric Blood Culture Media; Fungal Blood Culture Media
3) By Assay Kits And Reagents: Enzyme-Linked Immunosorbent Assay (ELISA) Kits; Polymerase Chain Reaction (PCR) Assay Kits; Immunoassay Reagents; Molecular Diagnostic Reagents; Biosensor-Based Assay Kits
4) By Software: Data Management Software; Laboratory Information Systems (LIS); Artificial Intelligence (AI)-Based Diagnostic Tools; Predictive Analytics Software; Cloud-Based Diagnostic Platforms
Which Competitive Trends Are Defining The Sepsis Diagnostics Market Structure?
Key companies operating within the sepsis diagnostics market are prioritizing the development of innovative solutions, such as culture-free diagnostic approaches, to enable the rapid and precise detection of sepsis without depending on conventional blood cultures. A culture-free diagnostic solution offers a method for identifying pathogens or infections without the necessity of traditional microbial culture techniques. These solutions leverage advanced technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), or immunoassays to quickly pinpoint pathogens directly from patient samples such as blood, saliva, or tissue. For example, in April 2024, Deepull Diagnostics S.L., a Spain-based manufacturing company, launched its UllCORE diagnostic system for the early detection of sepsis. The UllCORE system is a benchtop, culture-free multiplex PCR platform developed by Deepull for the swift identification of pathogens in sepsis and other acute infections. It extracts microbial DNA from 8 mL of whole blood, providing 50 reportable results within one hour. This system can detect 95% of sepsis-causing pathogens, including bacteria, fungi, and antibiotic resistance genes. Designed to improve early diagnosis and reduce the misuse of antibiotics, UllCORE assists hospitals in combating antimicrobial resistance.
Which Major Industry Participants Are Leading The Sepsis Diagnostics Market Growth?
Major companies operating in the sepsis diagnostics market are Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, Koninklijke Philips N.V., GE Healthcare, Wolters Kluwer N.V., bioMérieux S.A., Bruker Corporation, DiaSorin S.p.A., Cepheid Inc., Seegene Inc., Luminex Corporation, T2 Biosystems Inc., Cytovale Inc., Accelerate Diagnostics Inc., Immunexpress Inc., Sepsis Alliance
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/sepsis-diagnostics-global-market-report
How Do Regional Market Performances Compare Within The Sepsis Diagnostics Industry?
North America was the largest region in the sepsis diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Sepsis Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23514&type=smp
Browse Through More Reports Similar to the Global Sepsis Diagnostics Market 2025, By The Business Research Company
Diagnostic And Monitoring Ophthalmic Devices And Equipment Market 2025
Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025
Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model